SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Munoz N,Bosch FX,De Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348: 518527.
  • 2
    Wheeler CM. Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. Nat Clin Pract Oncol. 2007; 4: 224235.
  • 3
    Huh WK, and the Quadrivalent HPV Vaccine Phase IIb/IIIb Investigator. Impact of quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle vaccine on the incidence of abnormal pap tests and cervical procedures [abstract]. Gynecol Oncol. 2008; 108( suppl 1): s11. Abstract presented at Annual Meeting of Society of Gynecology Oncologists, March 9, 2008, Tampa, Florida.
  • 4
    Singh GK,Miller BA,Hankey BF,Edwards BK. Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage, and survival, 1975-2000. Cancer. 2004; 101: 1051107.
  • 5
    U.S. Cancer Statistics Working Group. United States Cancer Statistics: 2002 Incidence and Mortality. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2005.
  • 6
    Adams SH,Newacheck PW,Park JM,Brindis CD,Irwin CE. Health insurance across vulnerable ages: Patterns and disparities from adolescence to the early 30s. Pediatrics. 2007; 119: e1033e1039.
  • 7
    Cohen RA,Martinez ME. Health insurance coverage: early release of estimates from the National Health Interview Survey. Clin Exp Obstet Gyn. 2006;(document posted 2007 June 25, website updated 2007 July 9, cited 2007 July 12). Available at: http://www.cdc.gov/nchs/nhis.htm Accessed July 12, 2007.
  • 8
    Dubard CA,Massing MW. Trends in emergency Medicaid expenditures for recent and undocumented immigrants. JAMA. 2007; 297: 10851092.
  • 9
    Markowitz LE,Dunne EF,Saraiya M,Lawson HW,Chesson H,Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR. 2007; 56(RR-2): 124.
  • 10
    Public Law 101-354. Title 42. The Public Health and Welfare. Chapter 6a, The Public Health Service. Preventive Health Measures with Respect to Breast and Cervical Cancers 42. U.S.C. § 300k, US Congress 1990.
  • 11
    Centers for Disease Control and Prevention. National Breast and Cervical Cancer Early Detection Program. Page last updated: February 25, 2008. Available at: http://www.cdc.gov/cancer/nbccedp/about.htm Accessed on July 29, 2008.
  • 12
    Saraiya M,Irwin KL,Carlin L, et al. Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Cancer. 2007; 110: 10241032.
  • 13
    Swan J,Breen N,Coates R,Rimer B,Lee N. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003; 97: 15281540.
  • 14
    Benard V,Coughlin SS,Thompson T,Richardson LC. Cervical cancer incidence in the United States by area of residence, 1998-2001. Obstet Gynecol. 2007; 110: 681686.
  • 15
    McDougall J,Madeleine MM,Daling JR,Li C. Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992-2003. Cancer Causes Control. 2007; 18: 11751186.
  • 16
    Saraiya M,Ahmed F,King J, et al. Cervical cancer incidence in a pre-vaccine era—United States, 1998-2002. Obstet Gynecol. 2007; 109: 360370.
  • 17
    Centers for Disease Control and Prevention. Recruitment. The National Breast and Cervical Cancer Early Detection Program Manual. Atlanta, Georgia: US Department of Health and Human Services; 2007.
  • 18
    Centers for Disease Control and Prevention. Report to Congress on 317 Immunization Program. Atlanta, Georgia: US Department of Health and Human Services; 2007.
  • 19
    Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years—United States, 2008. MMWR. 2008; 57: Q1Q4.
  • 20
    Centers for Disease Control and Prevention. Recommended adult immunization schedule—United States, October 2007-September 2008. MMWR. 2007; 56: Q1Q4.
  • 21
    Centers for Disease Control and Prevention. Vaccine Management Business Improvement Project; (document dated 2007 February, website updated 2007 April 9, cited 2007 October 4). Available at: http://www.cdc.gov/vaccines/about/pibs/downloads/vmbip.pdf Accessed October 4, 2007.
  • 22
    Orenstein WA,Mootrey GT,Pazol K,Hinman AR. Financing immunization of adults in the United States. Clin Pharmacol Ther. 2007; 82: 764768.
  • 23
    Santoli J,Rodewald L,Maes E,Battaglia M,Coronado V. Vaccines for Children Program, United States, 1997. Pediatrics. 1999; 104: e15.
  • 24
    Orenstein WA. The role of measles elimination in development of a national immunization program. Pediatr Infect Dis J. 2006; 25: 10931101.
  • 25
    Centers for Disease Control and Prevention. Which children are eligible for the VFC Program? 2008. Available at: http://www.cdc.gov/vaccines/programs/elig-scrn-rec.doc-req.htm Accessed on July 29, 2008.
  • 26
    Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2005; 54(RR-7): 121.
  • 27
    Centers for Disease Control and Prevention. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2006; 55(RR-3): 143.
  • 28
    Centers for Disease Control and Prevention. Adolescent immunization. In: 2008-2012 Immunization Program Operations Manual (document posted 2007 April 10, website updated 2007 October 2, cited 2008 February 1). Available at: http://www.cdc.gov/vaccines/vac-gen/policies/ipom/downloads/chp-06-adolescent-iz.pdf
  • 29
    Centers for Disease Control and Prevention. Notice to Readers: revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. MMWR. 2007; 56: 794795.
  • 30
    Orenstein WA. Testimony on the immunization grant program of the PHS Act, 1997. Available at: http://www.hhs.gov/asl/testify/t970506a.html. Accessed archive page April 25, 2008.
  • 31
    Centers for Disease Control and Prevention. CDC vaccine price list; 2008. Available at: http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm (updated 2008 February 5). Accessed February 20, 2008.
  • 32
    Roush SW,Murphy TV, and the Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA. 2007; 298: 21552163.
  • 33
    Wooten KG,Darling N,Singleton JA,Shefer A. National, state, and local area vaccination coverage among children aged 19-35 months—United States, 2006. MMWR. 2007; 56: 880885.
  • 34
    Rein DB,Honeycutt AA,Rojas-Smith L,Hersey JC. Impact of the CDC's Section 317 Immunization Grants Program Funding on childhood vaccination coverage. Am J Public Health. 2006; 96: 15481553.
  • 35
    Castle PE,Solomon D,Saslow D,Schiffman M. Commentary. Predicting the effect of successful HPV vaccination on existing US cervical cancer prevention programs. Cancer. 2008; 113(10 suppl): 30313035.
  • 36
    Dasbach EJ,Elbasha EH,Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev. 2006; 28: 88100.
  • 37
    Goldie SJ,Kohli M,Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004; 96: 604615.
  • 38
    Kulasingam SL,Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003; 290: 781789.
  • 39
    Taira AV,Neukerman CP,Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2007; 10: 19151923.
  • 40
    Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer. 2007; 111: 145153.
  • 41
    Steinbrook R. The potential of human papillomavirus vaccines. N Engl J Med. 2006; 354: 11091112.
  • 42
    Sanders GD. Cost effectiveness of a potential vaccine forhuman papillomavirus. Emerg Infect Dis. 2003; 9: 3748.
  • 43
    Follen M,Richards-Kortum R. Emerging technologies and cervical cancer. J Natl Cancer Inst. 2000; 92: 363365.
  • 44
    Insinga RP,Dasbach EJ,Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics. 2005; 23: 11071122.
  • 45
    Schiller JT. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol. 2004; 2: 343347.
  • 46
    Benard VB,Eheman CR,Lawson HW, et al. Cervical screening in the National Breast and Cervical Cancer Early Detection Program, 1995-2001. Obstet Gynecol. 2004; 103: 564571.
  • 47
    Benard VB,Lawson HW,Eheman CR,Anderson C,Helsel W. Adherence to guidelines for follow-up of low-grade cytologic abnormalities among medically underserved women. Obstet Gynecol. 2005; 105: 1323138.
  • 48
    Centers for Disease Control and Prevention (CDC). The National Breast and Cervical Cancer Early Detection Program: 1991-2002 National Report. Atlanta, Georgia: Department of Health and Human Services; 2005.
  • 49
    Winer RL,Lee S-K,Hughes JP,Adam DE,Kiviat NB,Koutsky LA. Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003; 157: 218226.
  • 50
    Dunne EF,Unger ER,Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007; 297: 813819.
  • 51
    Newall AT,Beutels P,Wood JG,Edmunds WJ,MacIntyre CR. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis. 2007; 7: 289296.
  • 52
    Ekwueme DU,Gardner JG,Subramanian S,Tangka FK,Bapat B,Richardson LC. Cost analysis of the National Breast and Cervical Cancer Early Detection Program—selected states. Cancer. 2008; 112: 626635.
  • 53
    Helms LJ,Melnikow J. Determining costs of health care services for cost-effectiveness analyses: the case of cervical cancer prevention and treatment. Med Care. 1999; 37: 652661.
  • 54
    Myers ER,Mccrory DC,Subramanian S,Mccal N,Nanda K, et al. Setting the target for a better cervical screening test: characteristics of a cost-effective test for cervical neoplasia screening. Obstet Gynecol. 2000; 96: 645652.
  • 55
    Kulasingam SL,Kim JJ,Lawrence WF, et al. Cost effectiveness analysis based on the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst. 2006; 98: 92100.
  • 56
    US Bureau of Labor and Statistics. Consumer price indexes: Bureau of Labor and Statistics, 2003. Washington, DC: US Bureau of Labor and Statistics; 2003. Available at: http://www.bls.gov/cpi/ Accessed August 27, 2007.